Journal of neurology, neurosurgery, and psychiatry
Lecanemab appropriate use recommendations for clinical practice in the UK.
Catherine J Mummery, Jill Rasmussen, Dan Blackburn, Elizabeth Coulthard, R Rhys Davies, Rachel Dorsey, Nick C Fox, Akram A Hosseini, Chineze Ivenso, Matthew Jones, Sean P Kennelly, Christopher Kipps, Daniel Lashley, Graham Mackay, Rashi Negi
Published: 202510.1136/jnnp-2025-336597
Abstract
Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4) heterozygotes or non…
Preview only. Read the full abstract at the source